文献速递血栓与止血

快速全自动凝血因子VIII抑制物检测方法的开发:对艾美赛珠单抗不敏感且最低定量限为0.2 BU/mL

Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL.
PubMed 文献 · J Thromb Haemost · 2024-07-09

本研究开发了一种以重组凝血因子VIII为底物的快速全自动凝血因子VIII抑制物检测方法,采用Ceveron s100分析仪,20分钟内出结果。60例非血友病患者平均滴度为0.0 BU/mL(标准差0.1),最低定量限0.2 BU/mL;28例抑制物阳性临床样本中,14例含艾美赛珠单抗、14例不含,不含艾美赛珠单抗的I型抑制物样本相关系数为1.0,所有样本变异系数<15%。

要点

  • 新方法以重组凝血因子VIII为底物,孵育10分钟,20分钟内出结果。
  • 最低定量限为0.2 BU/mL,空白限为0.1 BU/mL。
  • 不含艾美赛珠单抗的I型抑制物样本与Nijmegen法相关系数为1.0。

核心结论

  • 研究展示了灵敏且特异的快速全自动凝血因子VIII抑制物检测方法的开发数据,20分钟内出结果,较标准方法资源消耗更少,有潜力改善检测变异性。

研究设计与样本

  • 方法学开发研究,以全长重组凝血因子VIII(Kovaltry,Bayer)为抑制物底物替代血浆凝血因子VIII,在Ceveron s100分析仪(Technoclone)上实现全自动检测。
  • 样本与重组凝血因子VIII(1.0 U/mL)等体积混合,37 °C孵育10分钟,随后用动力学发色底物法分析剩余凝血因子VIII活性,无需预先校准凝血因子VIII活性即可计算抑制物活性。
  • 在60例非血友病患者中评估滴度,在28例抑制物阳性临床样本(14例含艾美赛珠单抗、14例不含)中与Nijmegen法比较。
  • 通过加标实验排除方法对艾美赛珠单抗的依赖性;在3个实验室对7份样本每天检测2次、连续5天评估重复性。

主要发现

  • 60例非血友病患者平均滴度为0.0 BU/mL(标准差0.1),空白限为0.1 BU/mL,最低定量限为0.2 BU/mL。
  • 在不含艾美赛珠单抗的I型抑制物样本中,新方法与Nijmegen法的相关系数为1.0。
  • 加标实验排除了方法对艾美赛珠单抗的依赖性。
  • 重复性实验中所有样本的变异系数均<15%。

关键数值与推荐

  • 60例非血友病患者平均滴度为0.0 BU/mL(标准差0.1),空白限0.1 BU/mL,最低定量限0.2 BU/mL。
  • 不含艾美赛珠单抗的I型抑制物样本中,新方法与Nijmegen法相关系数为1.0。
  • 重复性实验中所有样本变异系数<15%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Factor (F)VIII inhibitors are measured using labor- and resource-expensive Nijmegen or Bethesda assays, which lack sensitivity for low-titer inhibitors and show high variations in quality surveys, mainly because of manual assay procedures. OBJECTIVES: The goal of this study was the development of a fast and fully automated FVIII inhibitor assay by using recombinant (r)FVIII as substrate and dedicated equipment for execution of the test. METHODS: A new rapid, fully automated, FVIII inhibitor assay is presented, the core of which is use of full-length recombinant FVIII (rFVIII; Kovaltry, Bayer) as inhibitor substrate instead of plasma FVIII, resulting in rapid binding of inhibitors to rFVIII due to absence of von Willebrand factor. Dramatic shortening of incubation time facilitated full automation on an analyzer capable of 3 subsequent sample dilution steps and 3 reagent additions. Equal volume mixtures of sample and rFVIII (1.0 U/mL) were incubated for 10 minutes at 37 °C, whereafter remaining FVIII activity was analyzed with a kinetic chromogenic assay, allowing inhibitor activity calculation without preceding FVIII activity calibration, using a Ceveron s100 analyzer (Technoclone). RESULTS: Mean titer in 60 nonhemophiliacs was 0.0 BU/mL (SD, 0.1), yielding a limit of blank of 0.1 BU/mL and lower limit of quantification of 0.2 BU/mL. Analyses were performed with the new method and a Nijmegen assay in 28 inhibitor-positive clinical samples, 14 containing emicizumab and 14 without. Correlation coefficient in emicizumab-free type I inhibitor samples was 1.0. Emicizumab dependency of the method was excluded in spiking experiments with inhibitor-positive samples. Reproducibility was tested by analyzing 7 samples in 3 laboratories for 5 days, twice daily; coefficients of variation of all samples were <15%. CONCLUSION: We present development data of a sensitive and specific rapid, automated FVIII inhibitor assay generating results within 20 minutes that is less resource-intensive than standard assays with potential to improve assay variability.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Verbruggen B, Binder NB, van Velp PJC, et al. Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL. J Thromb Haemost. 2024. PMID: 38992344. doi:10.1016/j.jtha.2024.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。